No Data
Express News | Purple Biotech Advances NT219 Into a Phase 2 Study In Head And Neck Cancer
Purple Biotech Advances NT219 Into Phase 2 Head and Neck Cancer Trial
Purple Biotech Partners With Mount Sinai to Advance Cancer Immunotherapy
Purple Biotech Announces Research Collaboration With Icahn School of Medicine
Express News | Purple Biotech Announces Research Collaboration With the Icahn School of Medicine at Mount Sinai for Captn-3 Tri-Specific Antibody Platform
Purple Biotech Expands ATM Offering by $1.33 Million
